Literature DB >> 29367369

Optimal approach to assessing T-cell function in haematopoietic cell transplant recipients.

Joshua M Dorn1, Roshini S Abraham2, Vilmarie Rodriguez3, Shakila P Khan3, Heather Stefanski4, Avni Joshi5.   

Abstract

Standardised approaches to functional immune assessment after haematopoietic cell transplantation (HCT) are lacking. A 12-year-old girl with relapsed acute myelogenous leukaemia, 2 years post-unrelated HCT, underwent immunological evaluation prior to receiving live vaccinations. Assessment of standard immune parameters and T-cell proliferation to phytohaemagglutinin was reassuring. She was given Varicella vaccination based on usual post-transplant protocols but was hospitalised 10 days later with localised Varicella infection (vaccine strain). Following recovery, she underwent further assessment that showed reduced T-cell proliferation to an anti-CD3 stimulation panel (anti-CD3 alone, soluble anti-CD3+ anti-CD28 and soluble anti-CD3+ plus exogenous IL-2). On reassessment, 7 months later, T-cell responses to anti-CD3 stimulation were normal and she was revaccinated without further incident. Measurement of T-cell proliferation to anti-CD3 stimulants likely yields more useful information about global T-cell function and should be strongly considered prior to live vaccine administration post-allogeneic haematopoietic transplant. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  immunological products and vaccines; immunology; infections; malignant disease and immunosuppression; vaccination/immunisation

Mesh:

Substances:

Year:  2018        PMID: 29367369      PMCID: PMC5786936          DOI: 10.1136/bcr-2017-222417

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  12 in total

1.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 2.  Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update.

Authors:  Ruth Seggewiss; Hermann Einsele
Journal:  Blood       Date:  2010-03-09       Impact factor: 22.113

3.  Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes.

Authors:  P D E Miller; T I de Silva; R Skinner; M Gilleece; A Peniket; A Hamblin; D Greenfield; C Anthias; K Peggs; A Madrigal; J A Snowden
Journal:  Bone Marrow Transplant       Date:  2017-01-23       Impact factor: 5.483

4.  T cell regeneration in pediatric allogeneic stem cell transplantation.

Authors:  H Olkinuora; K Talvensaari; T Kaartinen; S Siitonen; U Saarinen-Pihkala; J Partanen; K Vettenranta
Journal:  Bone Marrow Transplant       Date:  2007-01-08       Impact factor: 5.483

5.  Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice.

Authors:  E J Ariza-Heredia; A M Gulbis; K R Stolar; P Kebriaei; D P Shah; K K McConn; R E Champlin; R F Chemaly
Journal:  Transpl Infect Dis       Date:  2014-11-18       Impact factor: 2.228

Review 6.  Live (vaccines) from New York.

Authors:  C J Forlenza; T N Small
Journal:  Bone Marrow Transplant       Date:  2012-08-13       Impact factor: 5.483

7.  Immunization practices in acute lymphocytic leukemia and post-hematopoietic stem cell transplant in Canadian Pediatric Hematology/Oncology centers.

Authors:  Karina A Top; Anne Pham-Huy; Victoria Price; Lillian Sung; Dat Tran; Wendy Vaudry; Scott A Halperin; Gaston De Serres
Journal:  Hum Vaccin Immunother       Date:  2016-03-10       Impact factor: 3.452

Review 8.  Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution.

Authors:  Coco de Koning; Stefan Nierkens; Jaap Jan Boelens
Journal:  Blood       Date:  2016-10-03       Impact factor: 22.113

9.  Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Takahiro Aoki; Katsuyoshi Koh; Yutaka Kawano; Makiko Mori; Yuki Arakawa; Motohiro Kato; Ryoji Hanada
Journal:  Biol Blood Marrow Transplant       Date:  2015-12-31       Impact factor: 5.742

10.  Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.

Authors:  Ana C Alho; Haesook T Kim; Marie J Chammas; Carol G Reynolds; Tiago R Matos; Edouard Forcade; Jennifer Whangbo; Sarah Nikiforow; Corey S Cutler; John Koreth; Vincent T Ho; Philippe Armand; Joseph H Antin; Edwin P Alyea; Joao F Lacerda; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.